Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Coherus Oncology (CHRS) Leases (2019 - 2025)

Coherus Oncology's Leases history spans 8 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Leases fell 34.64% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $3.0 million, down 34.64%, while the annual FY2025 figure was $3.0 million, 34.64% down from the prior year.
  • Leases for Q4 2025 was $3.0 million at Coherus Oncology, down from $4.5 million in the prior quarter.
  • Across five years, Leases topped out at $5.9 million in Q4 2023 and bottomed at $1.2 million in Q4 2021.
  • The 5-year median for Leases is $2.8 million (2022), against an average of $3.1 million.
  • The largest annual shift saw Leases tumbled 86.92% in 2021 before it surged 128.79% in 2023.
  • A 5-year view of Leases shows it stood at $1.2 million in 2021, then skyrocketed by 111.8% to $2.6 million in 2022, then soared by 128.79% to $5.9 million in 2023, then fell by 23.58% to $4.5 million in 2024, then crashed by 34.64% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Leases are $3.0 million (Q4 2025), $4.5 million (Q4 2024), and $5.9 million (Q4 2023).